DUBLIN--(BUSINESS WIRE)--The "Optical Coherence Tomography Angiography Equipment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type and End User" report has been added to ResearchAndMarkets.com's offering.
The optical coherence tomography angiography equipment market is projected to reach US$ 616.31 million by 2028 from US$ 388.50 million in 2021; it is expected to grow at a CAGR of 6.8% from 2021 to 2028.
The rising prevalence of several eye-related disorders, and the availability of cost-efficient diagnosis methods fuel the growth of the optical coherence tomography angiography equipment market. According to the World Health Organization (WHO) report, globally at least 2.2 billion people suffer from a near or distance vision impairment. Of these, at least 1 billion, or almost half of these cases, can be prevented through incorporation of advanced technology for early detection of ophthalmic disorders among patient's group.
For records, 1 billion people include those with moderate or severe distance vision impairment or blindness owing to unaddressed refractive error (88.4 million), cataract (94 million), glaucoma (7.7 million), corneal opacities (4.2 million), diabetic retinopathy (3.9 million), and trachoma (2 million), and near vision impairment disorders caused due to unaddressed presbyopia (826 million).
According to the Optica Publishing Group report, OCTA has become an essential tool for retinal health evaluation among adults and is gaining strong attention due to its noninvasive method that involved in producing objective biomarkers (an objective indication of medical state observed from outside the patient that can be measured accurately) resulting in earlier and more effective diagnosis for retinal diseases.
Additionally, OCTA has been recommended as a standard of care in adult retinal practices due to its features such as the ability to identify subclinical disease and track disease progression in the majority of cases of blindness. Furthermore, fast product approval for optical coherence tomography angiography equipment by the Food and Drug Administration (FDA) enhances the utilization of such advanced technology.
The optical coherence tomography angiography equipment market has been analyzed on the basis of type and end user. Based on type, the market is bifurcated into handheld type and tabletop type. The tabletop type segment is estimated to account for a larger market share for optical coherence tomography angiography equipment during 2021-2028.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the optical coherence tomography angiography equipment market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global optical coherence tomography angiography equipment market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Market Dynamics
Drivers
- Rising Prevalence of Eye-Related Disorders
- Rise in Geriatric Population
Restraints
- Lack of Skilled Professionals and System Challenges
Opportunities
- Technological Innovation in OCT Angiography Devices
Future Trends
- Artificial Intelligence in OCT Angiography
Companies Mentioned
- NIDEK CO., LTD.
- Carl ZEISS AG
- OPTOVUE, INCORPORATED
- Canon Inc.
- OPTOPOL TECHNOLOGY SP. Z O.O
- Alcon Inc.
- Michelson Diagnostics Ltd.
- Topcon Corporation
- SANTEC Corporation
- HEIDELBERG ENGINEERING GMBH.
For more information about this report visit https://www.researchandmarkets.com/r/lmgk6f
